2021-05-29| Asia-PacificR&D

HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs

by Kathy Huang
Share To

Jin Li, Chairman & CEO of HitGen Image source:

China-based pharmaceutical company HitGen has announced a research collaboration with Dorian Therapeutics on May 24th. Under the agreement, HitGen will receive an undisclosed upfront payment from Dorian.

HitGen, renowned for its DNA-encoded libraries (DEL) in early drug discovery and is profited by it. DEL enables the synthesis and screening of unprecedented chemicals more efficiently, and it is now available for over 1 trillion DNA-encoded compounds. The collaboration with Dorian shows HitGen’s ambition to expand its pharmaceutical business in age-related diseases.


Senoblockers – Treatments Enhancing Regenerative Capacity of Aging cells

Senoblockers are treatments for aging diseases developed by Dorian. They act on aged tissues to reactivate the generation of cells, which provide therapeutics for aging diseases like Alzheimer’s, osteoporosis, and autoimmune diseases. HitGen will apply its platform technology to those disease targets senoblockers treat for.


Previous Collaborations

On April 6th, HitGen signed a drug discovery collaboration with BioAge, a company specializing in building biobanks that identify drug targets of elderly diseases. The partnership with BioAge and Dorian has the potential for HitGen to open up markets on age-associated diseases.

“We look forward to working with Dorian to identify novel small molecule starting points from DNA-encoded libraries,” Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, “We will work closely with Dorian scientists to generate new lead compounds for their research programs to address unmet medical needs associated with aging.”

Related Article: AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China


© All rights reserved. Collaborate with us:
Related Post
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
HitGen Ink Deal with Cambridge Molecular to Create a Deep Learning-Driven Drug Discovery Platform
Silicon Valley Startup, Altos Labs Attracts Funds From Billionaires To Chase Immortality
With A New Medical Device and Accompanying Platform, Roche Advances its Digital Ecosystem
Sanofi Licenses ABL Bio’s Bispecific Antibody for Parkinson’s Disease
SK Life Science Steps Forward in Treating Seizure Disorders
JPM22 Highlights: Amgen Sees Potential in Arrakis, Freenome Gets Boosted by Roche Again
JPM22 Highlights: Innovative Partnerships to Reimagine Personalized Care
GeneOnline’s Top 10 M&As of 2021
JPM22 Highlights: Cell and Gene Therapies Rise Up
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!